Name (Synonyms) | Correlation | |
---|---|---|
drug730 | NO-Immunosuppressive Wiki | 0.58 |
drug1329 | less-frequency hemodialysis Wiki | 0.58 |
drug1300 | dialysis Wiki | 0.58 |
drug147 | Best Practice Wiki | 0.58 |
drug568 | Immunoglubulins Wiki | 0.58 |
drug570 | Immunosuppressive Wiki | 0.58 |
drug1168 | Tocilizumab Wiki | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.33 |
D003324 | Coronary Artery Disease NIH | 0.33 |
D020521 | Stroke NIH | 0.29 |
D008173 | Lung Diseases, Obstructive NIH | 0.26 |
D009369 | Neoplasms, NIH | 0.17 |
D007239 | Infection NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
HP:0006510 | Chronic obstructive pulmonary disease HPO | 0.33 |
HP:0001297 | Stroke HPO | 0.29 |
HP:0006536 | Obstructive lung disease HPO | 0.26 |
HP:0002664 | Neoplasm HPO | 0.17 |
There are 3 clinical trials
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsFacing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients
Description: Time to all-cause and cardiovascular death
Measure: Mortality Time: From date of beginning of the study until the date of death assessed up to 52 weeksDescription: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.
Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate, Time: From date of beginning of the study assessed up to 52 weeksDescription: Time to first hospitalization of any cause
Measure: Hospitalization Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeksDescription: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the study
Measure: Vascular Access Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeksStarting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing. We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.
Description: serology to test for IgG and IgM antibodies against SARS-CoV-2
Measure: Antibodies against SARS-CoV-2 Time: one year